Serum oncostatin M in multiple myeloma: association with prognostic factors.
The serum concentration of oncostatin M (OSM) was measured in 40 multiple myeloma patients at diagnosis. Serum OSM level exceeded the sensitivity limit of the ELISA assay in eight (20%) of these patients (OSM+ patients). The serum levels of IL-6, another member of the gp180 cytokine family and C-reactive protein (CRP) as a surrogate of IL-6 were significantly higher in OSM+ patients. There was a trend towards higher serum beta 2M concentration in OSM+ patients, whereas there was no difference in the serum sIL-6R level or clinical data (age, gender, myeloma protein or stage) between the two groups. Two human myeloma cell lines secreted OSM and IL-6, but not IL-11 or leukaemia inhibitory factor (LIF), which suggests an important role for OSM and IL-6 in supporting growth of myeloma cells.
Koskela
K
K
Department of Medicine, Turku University Central Hospital, Finland.
Pelliniemi
T T
TT
Remes
K
K
Rajamäki
A
A
Pulkki
K
K
D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D053683:Oncostatin M; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured; D001613:beta 2-Microglobulin / Q000032:analysis
D015850:Interleukin-6; C508351:OSM protein, human; D010455:Peptides; D001613:beta 2-Microglobulin; D053683:Oncostatin M; D002097:C-Reactive Protein